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Relevance & Audiences 
Cognitive dysfunction is a feature often encountered in a broad spectrum of 
neurological and psychiatric conditions. These cognitive deficits are most 
commonly found in patients suffering from Alzheimer’s disease (AD), dementia, 
schizophrenia, stroke, attention deficit hyperactivity disorder (ADHD) and aging. 
Ameliorating these dysfunctions can dramatically improve the quality of life of 
patients. Hence, developing treatments, or ‘cognition enhancers’ (nootropics), is 
imperative in this respect. The studies described in this dissertation have mainly 
focused on cognitive impairments as encountered in AD and schizophrenia. The 
best known example is probably AD, in which memory problems are the major 
hallmark which place a tremendous burden on the quality of life of patients. 
 
AD is the most common form of elderly dementia. In 2010, the World Health 
Organization estimated that 35.6 million people worldwide suffered from 
dementia. Mainly due to the increasing aging of the world population, over 115 
million people will be suffering from this disease by the year 2050. A substantial 
majority of these cases will be due to Alzheimer’s pathology. 40% of AD patients 
will require intensive nursing home care, which will lead to a massive economic 
burden on social health care resources. There are five approved cognition 
enhancers for AD on the market which either modulate the cholinergic system 
by inhibition of acetylcholinesterase (AChE) or presumably reduce glutamate 
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neurotoxicity via NMDA antagonism. However, all have limited efficacy and 
severe side-effects. The etiology of AD is not well understood and current 
treatment for AD is ineffective both in combating cognitive deficiencies as well 
as in stopping disease progression. Thus, AD represents one of the major unmet 
medical needs for our lifetime.  
 
The economic burden of AD patient care is enormous. In 2014, the direct costs 
to the American society of caring for those with AD will total an estimated $214 
billion, including $150 billion in costs of medical care. This is expected to 
increase to over $1 trillion by 2050 in the US alone. Extension of 
institutionalization of only one year will already greatly reduce these future 
costs. Cognition enhancers can contribute to this extension of 
institutionalization by restoring cognitive functioning and hence independent 
living. 
 
Schizophrenia is a disabling psychiatric disorder that affects about 1% of the 
population worldwide. It has a major negative influence on the quality of life of 
patients. The disease is associated with a significant and long-lasting health, 
social and financial burden, not only for the patients (60% is unemployed), but 
also for families, other caregivers and the wider society. The extent of cognitive 
deficiencies is the best predictor of functional outcome when compared to the 
positive and negative symptomatology. At the same time, the cognitive 
demands of today’s society increase due to the increased flow of information 
via internet, television and cell phones in daily life as well as at work. However, 
the current available antipsychotic drugs are not effective in treating cognitive 
symptoms. Development of treatment for cognitive impairments will have a 
substantially beneficial effect on the functional outcome of patients, making it 
possible again to read a book or have a (telephone) conversation. Such a 
treatment will considerably improve the quality of life of the patient and will 
additionally have a significant social and economic impact, if the patients can 
return to work. In addition to the social and economic benefits, the effect of this 
return to independence would considerable improve the patient’s self-esteem. 
If such a cognition enhancer is available, it could be a major breakthrough. 
 
In addition, most neurodegenerative and psychiatric disorders have cognitive 
impairments for which no treatment exists. This explains the need and still 
ongoing search for better cognition enhancers. α7 nicotinic acetylcholine 
receptor (α7 nAChRs) ligands are relatively new drugs in this respect. 
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In this dissertation I showed that the cognitive performance of rodents can be 
improved by utilizing the α7 nAChR system.  
 
In summary, I showed:  
1. that α7 nAChR partial and full agonists have an acute positive effect on 
learning and memory;  
2. that continuous exposure to an α7 nAChR partial agonist did not lead to 
behavioral tolerance for at least up to 6 days of treatment; 
3. that combined treatment with suboptimal doses of an α7 nAChR partial 
agonist and an AChE inhibitor, which showed no effect when 
administered separately, led to improved cognitive performance; 
4. that low dose administration of α7 nAChR antagonists led to improved 
memory formation, hippocampal glutamate efflux and cognitive 
performance.  
 
It has been shown that α7 nAChRs are largely unaffected in the AD brain. Hence, 
different α7 nAChR agonists have been investigated for their potential to 
improve memory and attention disorders encountered in AD. A major drawback 
of α7 nAChRs is that they show rapid desensitization following repeated 
exposure to full agonists, thereby quickly inducing tolerance in patients taking 
medicines that agonistically target the α7 nAChRs. The studies in this 
dissertation indicated that using partial agonists, combinations of suboptimal 
doses of partial agonists and AChE inhibitors, and even antagonists might prove 
to be beneficial in AD. It is unlikely that these strategies will lead to the 
development of tolerance to the drugs.  
 
It has been hypothesized that amyloid plaques in AD brains are actually the lysis 
remnants of degenerated, beta amyloid peptide 42 (Aβ42)-overburdened 
neurons. The most vulnerable neurons for Alzheimer pathology, in particular the 
toxic plaque formation, appear to be those that abundantly express the α7 
nAChR, and internalization of Aβ42 appears to be facilitated by the high-affinity 
binding of Aβ42 to the α7 nAChRs on neuronal cell surfaces. This is followed by 
endocytosis of the resulting complex and its accumulation within the lysosomal 
compartment thus results in amyloid plaque formation eventually. Elaborating 
on this, treatment with α7 nAChR ligands might reduce the disease progression 
via occupying these receptors and hence prevent Aβ42 from binding to the 
receptor. Therefore, these drugs may make the brain more resistant against the 
destructive effects of Aβ depositions. To summarize, α7 nAChR ligands might 
both directly improve learning and memory, while they also slow down actual 
disease progression. 
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Unravelling the working mechanisms of the α7 nAChRs will not only benefit AD. 
α7 nAChRs have been shown to be involved in other psychiatric conditions like 
schizophrenia and ADHD. For example in schizophrenia, preclinical and clinical 
studies have shown that α7 nAChR ligands were able to normalize the auditory 
gating deficit in both rodent models and in schizophrenic patients. In addition, 
when considering the cognitive symptoms of schizophrenia and the well-
established pro-cognitive effect α7 nAChR ligands have on cognition, it is likely 
that α7 nAChR ligands are beneficial as an add-on therapy in the treatment of 
schizophrenic patients. Also in ADHD, it is assumed α7 nAChR ligands can 
improve the symptoms of this disorder via stimulating working memory and 
attention processes. Therefore, α7 nAChR ligands can be expected to also be 
beneficial in these disorders. Until an actual cure is found for these disorders, 
symptomatic treatment will stay the most desirable solution for these patients. 
Relieving the symptoms of these disorders will already greatly improve the 
quality of life of patients.  
 
Furthermore, similar ion channels like GABAA, glycine and 5-HT3 would most 
likely function via a similar mechanism. This opens up a brand new view on 
these receptor subtypes to develop better treatments for a plethora of different 
neurological and psychiatric conditions.   
 
Clearly, the results from these studies are of interest for the pharmaceutical 
industry. Developing new (symptomatic) treatments for AD, schizophrenia or 
other neurological or psychiatric disorders in which cognition is impaired, is 
commercially interesting for industry. Actually industry is the stakeholder having 
the financial resources and infrastructure organization to bring a new drug to 
the market. Of note, part of research related to the drug EVP-6124 as described 
in this dissertation is a collaboration with its owner FORUM Pharmaceuticals 
(Boston, USA). In addition, research on the α7 nAChR antagonist Compound 7i is 
a collaboration with Intra-Cellular Therapies, Inc. (New York, USA). EVP-6214 (or: 
Encenicline) is currently in clinical phase III trials for AD and schizophrenia. 
 
In summary, the results of the studies described in this dissertation are of 
importance to patients, their family and caretakers, governments (reduction in 
medical costs) and pharmaceutical industries.   
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Activities/Products & Innovation 
Actual products which can be derived from the studies in this dissertation are 
improved pharmacological treatments for AD and schizophrenia patients. A big 
advantage of treatment with α7 nAChR partial agonists and antagonists is that 
desensitization of the receptors, and therefore tolerance to the drugs, does not 
develop. The development of tolerance is a known phenomenon for selective 
full agonists, and this resulted in the termination of most α7 nAChR programs in 
different pharmaceutical companies. Since α7 nAChRs are still abundantly 
present in the brains of AD patients, the target still seems promising. Partial 
agonists and antagonists of the α7 nAChR could therefore prove to be very 
beneficial in the functional outcome of AD patients.   
 
Furthermore, parallel studies with ‘follow-up’ compounds could be patented for 
new indications, like for example schizophrenia and ADHD. This opens up new 
possibilities for specific blocking/mild activation of α7 nAChRs. 
 
In conclusion, the findings of α7 nAChR partial agonists and antagonists to 
enhance α7 nAChR functioning and therefore learning and memory shed a new 
light on the α7 nAChR as a target for cognition enhancement and even 
neurodegenerative pathology reduction. 
